Dr. Benjamin B. Freeman, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 385
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA09429700
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Morristown Medical Center Morristown, NJ
- Cooperman Barnabas Medical Center Livingston, NJ
- Clara Maass Medical Center Belleville, NJ
Medical groups
- Barnabas Health Medical Group PC (1,070 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 385
- Services billed
- 4,712
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,036 | 313 |
| Insertion of needle into vein for collection of blood sample | 1,012 | 302 |
| Blood test, comprehensive group of blood chemicals | 684 | 256 |
| Established patient office or other outpatient visit, 40-54 minutes | 497 | 191 |
| Magnesium level | 489 | 189 |
| Phosphate level | 479 | 189 |
| Uric acid level, blood | 370 | 146 |
| Established patient office or other outpatient visit, 30-39 minutes | 262 | 161 |
| Gammaglobulin (immune system protein) measurement | 256 | 54 |
| Ferritin (blood protein) level | 188 | 106 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 119 |
| Prednisone Other prescribers in Morristown, NJ | 92 |
| Hydroxyurea Other prescribers in Morristown, NJ | 77 |
| Anastrozole Other prescribers in Morristown, NJ | 63 |
| Eliquis (apixaban) Other prescribers in Morristown, NJ | 62 |
| Nubeqa (darolutamide) | 61 |
| Xarelto (rivaroxaban) Other prescribers in Morristown, NJ | 34 |
| Letrozole Other prescribers in Morristown, NJ | 24 |
| Xtandi (enzalutamide) | 22 |
| Promacta (eltrombopag olamine) | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 25 payments worth $461 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $95.67 |
|---|---|
| Merck Sharp & Dohme LLC | $88.41 |
| Pfizer Inc. | $56.62 |
| Janssen Biotech, Inc. | $35.69 |
| E.r. Squibb & Sons, L.l.c. | $27.08 |
| Taiho Oncology, Inc. | $23.05 |
| Bayer HealthCare Pharmaceuticals Inc. | $22.44 |
| Lilly USA, LLC | $21.32 |
| Food and Beverage | $461 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $711,147 in research payments for these studies, mostly to the institutions running them.
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Beone Medicines Ltd. · Completed · NCT04116437 - A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Beone Medicines Ltd. · Active, not recruiting · NCT04170283 - A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants wi…
Merck Sharp & Dohme LLC - A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Beone Medicines Ltd. · Active, not recruiting · NCT03336333 - Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.